2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one,
APR-246,
PRIMA-1(MET),
APR-246,
PRIMA-1MET,
5291-32-7,
APR 246,
APR-246 (PRIMA-1MET),
2-(Hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one,
Prima 1MET,
2-(Hydroxymethyl)-2-(methoxymethyl)quinuclidin-3-one,
apr-246-prima-1met,
MLS006010767,
SCHEMBL2228161,
3-Quinuclidinone, 2-(hydroxymethyl)-2-(methoxymethyl)-,
CHEMBL3186011,
CTK8G2576,
PRIMA-1MET(APR-246),
BCP20294,
EX-A2772,
MFCD16294187,
s7724,
1-Azabicyclo(2.2.2)octan-3-one, 2-(hydroxymethyl)-2-(methoxymethyl)-,
AKOS024457764,
CS-7614,
DB11684,
SB19737,
KS-000006B8,
NCGC00346881-01,
HY-19980,
SMR004701457,
prima-1,
PRIMA-1-MET,
D03XTY,
PRIMA-1(MET),
UNII-Z41TGB4080,
APR-017,
APR-304,
APR-305,
APR-310,
Z41TGB4080,
P53 modulators (iv, cancer), Aprea,
A4484,
C533410,
Apoptosis stimulators (iv, cancer), Karolinska Institute,
2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one,
2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one,
Mutant p53 reactivation compounds (iv, cancer), Karolinksa Institute,